Zenas Biopharma (ZBIO) Competitors

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Do analysts rate BCRX or ZBIO?

BioCryst Pharmaceuticals presently has a consensus target price of $16.13, indicating a potential upside of 82.20%. Zenas Biopharma has a consensus target price of $40.00, indicating a potential upside of 245.42%. Given Zenas Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas Biopharma is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Zenas Biopharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to BCRX or ZBIO?

In the previous week, Zenas Biopharma had 21 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 29 mentions for Zenas Biopharma and 8 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.78 beat Zenas Biopharma's score of 0.03 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better valuation & earnings, BCRX or ZBIO?

Zenas Biopharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$450.71M	4.10	-$226.54M	-$0.43	-20.58
Zenas Biopharma	$5M	96.81	-$148.39M	-$3.55	-3.26

Is BCRX or ZBIO more profitable?

Zenas Biopharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -30.01%.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-30.01%	N/A	-24.06%
Zenas Biopharma	N/A	N/A	N/A

Do institutionals & insiders have more ownership in BCRX or ZBIO?

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in BCRX or ZBIO?

BioCryst Pharmaceuticals received 490 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 66.94% of users gave BioCryst Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
BioCryst Pharmaceuticals	Outperform Votes 492 66.94%	Underperform Votes 243 33.06%
Zenas Biopharma	Outperform Votes 2 100.00%	Underperform Votes No Votes

Summary

Zenas Biopharma beats BioCryst Pharmaceuticals on 9 of the 16 factors compared between the two stocks.